Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $835.37 | 56 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $157.45 | 9 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $88.96 | 6 | $0 (2023) |
| PFIZER INC. | $85.86 | 6 | $0 (2024) |
| Amgen Inc. | $67.68 | 4 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $58.92 | 5 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $56.51 | 3 | $0 (2020) |
| Astellas Pharma US Inc | $51.73 | 3 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $44.93 | 4 | $0 (2019) |
| GlaxoSmithKline, LLC. | $40.53 | 3 | $0 (2022) |
| ABBVIE INC. | $34.16 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $68.68 | 4 | PFIZER INC. ($30.69) |
| 2023 | $74.93 | 5 | AstraZeneca Pharmaceuticals LP ($16.70) |
| 2022 | $66.74 | 4 | Amgen Inc. ($35.51) |
| 2020 | $113.23 | 7 | AstraZeneca Pharmaceuticals LP ($59.62) |
| 2019 | $180.00 | 13 | Merck Sharp & Dohme Corporation ($33.53) |
| 2018 | $172.05 | 13 | Novo Nordisk Inc ($59.51) |
| 2017 | $159.74 | 10 | Novo Nordisk Inc ($85.69) |
All Payment Transactions
56 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/07/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: Cardio-renal | ||||||
| 06/10/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $20.07 | General |
| Category: NEUROSCIENCE | ||||||
| 03/25/2024 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $14.42 | General |
| Category: VACCINES | ||||||
| 01/04/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $16.27 | General |
| Category: PAIN | ||||||
| 11/13/2023 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: VACCINES | ||||||
| 08/18/2023 | Ironshore Pharmaceuticals Inc. | JORNAY PM (Drug) | Food and Beverage | Cash or cash equivalent | $14.47 | General |
| Category: CENTRAL NERVOUS SYSTEM STIMULANT | ||||||
| 07/10/2023 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: Biological | ||||||
| 02/14/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.70 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/06/2023 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $13.57 | General |
| Category: Bone Health | ||||||
| 11/21/2022 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: Bone Health | ||||||
| 11/07/2022 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $14.09 | General |
| Category: NEUROSCIENCE | ||||||
| 10/03/2022 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $17.14 | General |
| Category: RESPIRATORY | ||||||
| 06/27/2022 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: Inflammation | ||||||
| 03/02/2020 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $19.30 | General |
| Category: NEUROSCIENCE | ||||||
| 02/19/2020 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.57 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/29/2020 | Boehringer Ingelheim Pharmaceuticals, Inc. | STIOLTO RESPIMAT (Drug) | Food and Beverage | In-kind items and services | $21.22 | General |
| Category: RESPIRATORY | ||||||
| 01/28/2020 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.30 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/27/2020 | PFIZER INC. | CHANTIX (Drug), ELIQUIS | Food and Beverage | In-kind items and services | $13.09 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 01/22/2020 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/13/2020 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $11.47 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/17/2019 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $11.44 | General |
| Category: Neuroscience | ||||||
| 12/05/2019 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $12.64 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/18/2019 | Takeda Pharmaceuticals U.S.A., Inc. | Entyvio (Biological), Vyvanse, Trintellix | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: Lower GI | ||||||
| 11/11/2019 | PFIZER INC. | CHANTIX (Drug), EUCRISA, COLOGUARD | Food and Beverage | In-kind items and services | $15.49 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 11/06/2019 | Merck Sharp & Dohme Corporation | JANUVIA (Drug), JANUMET, BELSOMRA | Food and Beverage | In-kind items and services | $11.11 | General |
| Category: ENDOCRINOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 5 | 189 | 207 | $36,726 | $10,872 |
| 2021 | 18 | 1,447 | 1,737 | $257,742 | $120,088 |
| 2020 | 16 | 1,314 | 1,405 | $186,799 | $88,825 |
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 90 | 99 | $22,473 | $4,924 | 21.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 33 | 33 | $6,798 | $4,175 | 61.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 30 | 37 | $5,883 | $1,199 | 20.4% |
| G0009 | Administration of pneumococcal vaccine | Office | 2022 | 12 | 12 | $324.00 | $322.92 | 99.7% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 24 | 26 | $1,248 | $251.86 | 20.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 339 | 472 | $107,144 | $38,075 | 35.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 248 | 248 | $51,088 | $31,466 | 61.6% |
| 90670 | Pneumococcal vaccine for injection into muscle | Office | 2021 | 56 | 56 | $17,864 | $13,461 | 75.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 140 | 189 | $30,051 | $10,554 | 35.1% |
| 90732 | Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older | Office | 2021 | 63 | 63 | $10,332 | $7,609 | 73.6% |
| 90694 | Influenza virus vaccine, quadrivalent (aiiv4), inactivated, adjuvanted, preservative free, for injection into muscle, 0.5 ml dosage | Office | 2021 | 101 | 101 | $10,605 | $6,621 | 62.4% |
| 99495 | Transitional care management services, moderately complexity, requiring face-to-face visits within 14 days of discharge | Office | 2021 | 21 | 22 | $6,688 | $3,474 | 51.9% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2021 | 12 | 12 | $2,700 | $1,948 | 72.1% |
| G0009 | Administration of pneumococcal vaccine | Office | 2021 | 107 | 117 | $3,159 | $1,841 | 58.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 116 | 117 | $3,159 | $1,825 | 57.8% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 122 | 140 | $6,720 | $1,313 | 19.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 14 | 14 | $4,368 | $1,047 | 24.0% |
| 90686 | Vaccine for influenza for administration into muscle, 0.5 ml dosage, quadrivalent, preservation free | Office | 2021 | 17 | 17 | $612.00 | $345.21 | 56.4% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 26 | 28 | $1,288 | $269.75 | 20.9% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 12 | 12 | $528.00 | $124.86 | 23.6% |
| 81003 | Automated urinalysis test | Office | 2021 | 28 | 29 | $348.00 | $65.25 | 18.8% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2021 | 11 | 44 | $528.00 | $42.51 | 8.1% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2021 | 14 | 56 | $560.00 | $6.10 | 1.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 292 | 292 | $60,152 | $32,617 | 54.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 170 | 218 | $44,036 | $13,493 | 30.6% |
About Dr. Phillip Williams, DO
Dr. Phillip Williams, DO is a Family Medicine healthcare provider based in Grove, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/05/2011. The National Provider Identifier (NPI) number assigned to this provider is 1245522549.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Phillip Williams, DO has received a total of $835.37 in payments from pharmaceutical and medical device companies, with $68.68 received in 2024. These payments were reported across 56 transactions from 18 companies. The most common payment nature is "Food and Beverage" ($835.37).
As a Medicare-enrolled provider, Williams has provided services to 2,950 Medicare beneficiaries, totaling 3,349 services with total Medicare billing of $219,785. Data is available for 3 years (2020–2022), covering 39 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Location Grove, OK
- Active Since 05/05/2011
- Last Updated 08/27/2020
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1245522549
Products in Payments
- Victoza (Drug) $109.15
- FARXIGA (Drug) $88.96
- TRELEGY ELLIPTA (Drug) $40.53
- Myrbetriq (Drug) $37.68
- JARDIANCE (Drug) $35.29
- JANUVIA (Drug) $33.85
- EVENITY (Biological) $31.23
- PREVNAR 20 (Biological) $30.56
- CHANTIX (Drug) $28.58
- XARELTO (Drug) $25.60
- Trintellix (Drug) $24.32
- Xultophy 100/3.6 (Drug) $22.40
- EMGALITY (Drug) $21.93
- STIOLTO RESPIMAT (Drug) $21.22
- UBRELVY (Drug) $20.07
- TRINTELLIX (Drug) $19.30
- Aimovig (Biological) $18.60
- LINZESS (Drug) $18.37
- Kerendia (Drug) $17.92
- Otezla (Drug) $17.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Grove
Jacob Hostetler, M.d, M.D
Family Medicine — Payments: $7,781
Dr. Jenny Walsh, M.d, M.D
Family Medicine — Payments: $2,492
Dr. Charles Chouteau, Md, MD
Family Medicine — Payments: $2,435
Daniel Nicoll, Do, DO
Family Medicine — Payments: $426.45
Dr. Trevor Kitchens, Md, MD
Family Medicine — Payments: $388.36
Dr. Kyle Schauf, Md, MD
Family Medicine — Payments: $223.70